13 terminated. 13 Phase 2, 4 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Terminated 13 |
| Phase 1 | 4 | Terminated 4 |
| Phase 3 | 2 | Terminated 2 |
Follow Foot Ulcer: new trials by email Literature Review of Foot Ulcer trials Research Report on Foot Ulcer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunonutrition for Diabetic Foot Ulcers Lovaza, L-Arginine Powder, Vitamin C - Diabetes Mellitus, Diabetic Peripheral Neuropathy | Phase 2 / Phase 3 | Terminated | Prisma Health-Midlands | 1 | 2023-02-08 | 2024-12-27 |
| Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers ILP100-Topical (emilimogene sigulactibac) 5x10^7 CFU/cm^2, ILP100-Topical (emilimogene sigulactibac) 1x10^9 CFU/cm^2, Placebo - Wound Heal, Wound Healing Disturbance of | Phase 2 | Terminated | Ilya Pharma | 1 | 2022-09-26 | 2025-03-05 |
| Nu-3 Topical Gel for Treatment of Diabetic Foot Ulcer 5% Bisphosphocin Topical Gel, Placebo Topical Gel, 10% Bisphosphocin Topical Gel - Chronic Diabetic Foot Ulcers | Phase 2 | Terminated | Lakewood-Amedex Inc | 3 | 2022-03-11 | 2024-01-30 |
| Application of S26E for Diabetic Foot Ulcer Healing Standard-of-care for neuropathic/neuroischemic diabetic foot ulcers, S26E - Diabetic Foot, Neuropathic Foot Ulcer | Phase 2 | Terminated | National and Kapodistrian University of Athens | 5 | 2020-05-15 | 2022-06-08 |
| Iontophoresis of Treprostinil to Enhance Wound Healing in Diabetic Foot Skin Ulcers Treprostinil iontophoresis, Remodulin® placebo iontophoresis - Diabetic Foot Ulcer | Phase 1 / Phase 2 | Terminated | University Hospital, Grenoble | 4 | 2020-01-28 | 2023-12-12 |
| Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD. PDA-002, Placebo - Peripheral Arterial Disease, Diabetic Foot | Phase 2 | Terminated | Celularity Incorporated | 159 | 2014-10-23 | 2026-06-12 |
| Safety and Efficacy of Gentamicin Topical Gel (AppliGel-G) for Treatment of Mild to Moderately Infected Diabetic Foot Ulcers Gentamicin Topical Gel, Ciprofloxacin, Doxycycline - Diabetic Foot Ulcers | Phase 1 / Phase 2 | Terminated | Royer Biomedical, Inc. | 9 | 2014-01-01 | 2015-05-14 |
| Proof of Concept (Design Validation) in Patient With Hard to Heal Wounds Such as Pressure Ulcer, Diabetic Foot Ulcer and Leg Ulcer, Leia Leia - Leg Ulcer, Diabetic Foot Ulcer | Phase 2 | Terminated | Molnlycke Health Care AB | 6 | 2013-09-01 | 2015-12-23 |
| The ASCEND Study: A Study to Investigate the Safety and Clinical Effect of Nexagon to Treat Slow Healing Diabetic Foot Ulcers Nexagon®, Nexagon® vehicle - Diabetic Foot Ulcer | Phase 1 / Phase 2 | Terminated | OcuNexus Therapeutics, Inc. | 24 | 2009-04-01 | 2010-08-31 |
| Prevention of Infection Using a Topical Gentamicin-Collagen Sponge in Diabetic Patients With An Uninfected Foot Ulcer gentamicin-collagen sponge, placebo collagen sponge - Diabetic Foot Ulcer | Phase 2 | Terminated | Innocoll | 49 | 2008-04-01 | 2012-03-23 |
| Safety and Preliminary Efficacy Study of Nicotine Gel to Treat Diabetic Foot Ulcers ATG002 (study drug) - Diabetic Foot Ulcers | Phase 1 / Phase 2 | Terminated | CoMentis | 48 | 2006-10-01 | 2007-08-09 |
| Safety and Efficacy Study of MRE0094 to Treat Large, Single or Multiple, Chronic, Neuropathic, Diabetic Foot Ulcers MRE0094, Vehicle gel - Foot Ulcer, Diabetic, Diabetes Complications | Phase 2 | Terminated | Pfizer | 16 | 2006-06-01 | 2012-06-01 |
| Efficacy of a Low-Molecular-Weight Heparin (Bemiparin) in the Treatment of Chronic Foot Ulcers in Diabetic Patients bemiparin (low molecular weight heparin) - Foot Ulcer, Diabetic, Diabetic Angiopathies | Phase 2 / Phase 3 | Terminated | Spanish National Health System | 84 | 2001-06-01 | 2006-11-14 |
Diabetic Foot (13) · Diabetes Mellitus (4) · Diabetes Complications (2) · Diabetic Angiopathies (2) · Leg Ulcer (2) · Cardiovascular Diseases (1) · Diabetic Neuropathies (1) · Disease (1) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · Infections (1) · Metabolic Diseases (1) · Peripheral Arterial Disease (1) · Pressure Ulcer (1)
Skin and Connective Tissue Diseases (13) · Cardiovascular Diseases (12) · Diabetic Neuropathies (12) · Endocrine System Diseases (12) · Skin Diseases (12) · Skin Ulcer (12) · Vascular Diseases (12) · Diabetes Complications (11) · Diabetic Angiopathies (11) · Leg Ulcer (11) · Diabetes Mellitus (9) · Foot Diseases (6) · Nutritional and Metabolic Diseases (4) · Glucose Metabolism Disorders (3)
2-(2-(4-chlorophenyl)ethoxy)adenosine (1) · Arginine (1) · Ascorbic Acid (1) · Ciprofloxacin (1) · Doxycycline (1) · Drug Evaluation (1) · Fatty Acids, Omega-3 (1) · Heparin, Low-Molecular-Weight (1) · Omacor (1) · Standard of Care (1) · bemiparin (1)
Celularity Incorporated (1) · CoMentis (1) · Ilya Pharma (1) · Innocoll (1) · Lakewood-Amedex Inc (1) · Molnlycke Health Care AB (1) · National and Kapodistrian University of Athens (1) · OcuNexus Therapeutics, Inc. (1) · Pfizer (1) · Prisma Health-Midlands (1) · Royer Biomedical, Inc. (1) · Spanish National Health System (1) · University Hospital, Grenoble (1)
United States (7) · Sweden (2) · France (1) · Greece (1) · New Zealand (1)
Cracowski Jean-luc, Professor (1) · David Prior (1) · Henry Hsu, MD (1) · J. Benjamin Jackson, MD (1) · Jan Apelqvist, MD/PhD (1) · Manuel Rullan, MD (1) · Robert L. Rolleri, Pharm.D. (1) · Sharmila Koppisetti, MD (1) · Sumita Paul, MD, MPH (1)